The Misuse of Drugs (Medicinal Cannabis) Amendment Bill is going through Parliament meaning the industry’s future is still uncertain.
But Mr Manning full confidence that developments to the law will go ahead.
‘The risk we’ll be managed is related to the conditions that exist in that bill’.
It’s critical that chronic pain and other health problems are included – Mr Manning said.
The company’s products will be priced at 15 cents per milligram – making it substantially cheaper than imported goods at 75 cents per milligram.
Affordability for the local market was key he said – but New Zealand was also well-placed to create premium products to sell on the rapidly-growing international market.